Harrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. Harrow owns U.S. commercial rights to ten FDA-approved ophthalmic pharmaceutical products. Harrow also owns and operates ImprimisRx, the leading U.S. ophthalmic‑focused pharmaceutical compounding business, which also serves as a mail-order pharmacy licensed to ship prescription medications in all 50 states. Harrow has non-controlling equity positions in Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc., companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in four late-stage drug candidates being developed by Surface and Melt.

Manufacturing

Pharmaceutical

Harrow

Harrow's headquarters in Nashville, TN, United States

Mark L. Baum

Adrienne Graves

Amir Shojaei

Lauren Silvernail

Garrett S.

Mark Mannebach

Kim Barratt

Andrew R. Boll

John P. Saharek

Marty Makary

Perry J. Sternberg

Richard L. Lindstrom

R. Lawrence Van Horn

Description

People (11)

Mark L. Baum

John P. Saharek

Andrew R. Boll

Kim Barratt

Chintan Dalwadi

Bruce Kent

Paulina Velazquez

Tyler Hooper

Garrett S.

Carl Pottkotter

Brett Burrell

Jobs